Edward K. Ainscow, Adrian Campbell, Michael Cripps, Robert Workman, Stuart Thomson, Kam Chohan, Samien Crepin, Mahiro Sunose, Jamie Patient, Jane Kendrew, Ash Bahl
Identification of an orally bioavailable dual Cyclin-K glue degrader – CDK12/13 inhibitor’
Dec. 01, 2021
Identification of novel CDK12 inhibitors that synergize with PARP inhibition through induction of ‘BRCAness’ phenotype
Jun. 01, 2020
Edward K. Ainscow
Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor-positive, HER2-negative breast cancer
Dec. 09, 2021
M.G. Krebs, S. Lord, L. Kenny, R.D. Baird, I. MacPherson, A. Bahl, G. Clack, E. Ainscow, A.G. Barrett, P. Dickinson, M.J. Fuchter, M. Lehnert, S. Ali, S. Mcintosh, R.S. Coombes
A clinical study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced triple negative breast cancer (TNBC)
Dec. 08, 2021
Sacha J Howell, Laura M Kenny, Simon Lord, Matthew G Krebs, Tobias Arkenau, Richard Baird, Iain R MacPherson, Ash Bahl, Glen Clack, Edward Ainscow, Athony GM Barrett, Paul A Dickinson, Matthew J Fuchter, Manfred Lehnert, Simak Ali, Stuart McIntosh, Charles Coombes
Study of samuraciclib(CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor-positive, HER2-negative breast cancer
Sep. 01, 2021
S.J. Howell, M.G. Krebs, S. Lord, L. Kenny, A. Bahl, G. Clack, E. Ainscow, H.I. Arkenau, J.L. Mansi, C. Palmieri, P. Richards, R. Jeselsohn, Z. Mitri, W.J. Gradishar, S. Sardesai, J. O'Shaughnessy, M. Lehnert, S. Ali, S. McIntosh, R.C. Coombes
The CDK7 inhibitor CT7001 (samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer
Jun. 29, 2022
Theodora A. Constantin, Anabel Varela-Carver, Kyle K. Greenland, Gilberto Serrano de Almeida, Lucy Penfold, Simon Ang, Alice Ormrod, Edward K. Ainscow, Ash K. Bahl, David Carling, Matthew J. Fuchter, Simak Ali, Charlotte L. Bevan
2.5 Angstrom – resolution structure of human CDK-activating kinase bound to the clinical inhibitor ICEC0942
Feb. 16, 2021
Basil J. Gerber, Johnathan Remis, Simak Ali, Eva Nogales
ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment - supplementary files
Mar. 01, 2018
ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment
Mar. 01, 2018
Hetal Petal, Manikandan Periyasamy, Georgina P Sava, Alexander Bondke, Brian W. Slafer, Sebastian H B Kroll, Marion Barbazanges, Richard Starkey, Silvia Ottaviani, Alison Harrod, Eric O Adoagye, Laki Buluwela, Matthew J Fuchter, Anthony G M Barrett, R Charles Coombes, Simak Ali